Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
September 11 2017 - 8:30AM
Novelion Therapeutics Inc. (NASDAQ:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare diseases, today announced the
appointment of Suzanne Bruhn, Ph.D. to its board of directors,
effective October 1, 2017.
Jason Aryeh, chairman of the board of directors,
said, “Dr. Bruhn brings to the Novelion Board of Directors
executive leadership, operational knowledge, deep scientific
expertise and corporate transactions acumen. We look forward to her
contributing to the strategic direction of Novelion as we seek to
maximize the value of our assets.”
Dr. Bruhn is president and chief executive
officer of Proclara Biosciences, Inc. Prior to joining Proclara,
Dr. Bruhn served as president and chief executive officer of
Promedior, Inc. She also served as a member of the board of
directors of Raptor Pharmaceuticals from 2011 until it was acquired
by Horizon Pharma in 2016. Previously, Dr. Bruhn served as senior
vice president, strategic planning and program management at Shire
from 1998 until 2012. Dr. Bruhn currently also serves on the board
of directors of Aeglea BioTherapeutics, Inc., a publicly traded
biotechnology company focused on the treatment of rare genetic
diseases and cancer, and Pliant Therapeutics, a private
biotechnology company. Dr. Bruhn received her B.S. degree in
Chemistry from Iowa State University and her Ph.D. in Chemistry
from Massachusetts Institute of Technology.
About Novelion
TherapeuticsNovelion Therapeutics is a biopharmaceutical
company dedicated to developing new standards of care for
individuals living with rare diseases. Novelion has a diversified
commercial portfolio through its indirect subsidiary, Aegerion
Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and
is also developing zuretinol acetate for the potential treatment of
inherited retinal disease caused by underlying mutations in RPE65
or LRAT genes. The company seeks to advance its portfolio of rare
disease therapies by investing in science and clinical
development.
CONTACT:Amanda Murphy, Director, Investor &
Corporate CommunicationsNovelion
Therapeutics857-242-5024amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024